Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Thyroid Function and Cardiovascular Disease: The Thy-CVD Cohort (Thy-CVD Cohort)

Dynamic Thyroid Function Exposure, Cardiovascular Remodeling, and Clinical Outcomes: A Nationwide Multicenter Ambidirectional Cohort Study

The goal of this multicenter observational study is to investigate the relationship between thyroid function, changes in thyroid hormone levels over time, and cardiovascular diseases in adults. The main questions it aims to answer are:

Are different thyroid function states and long-term changes in thyroid hormone levels associated with the risk of major adverse cardiovascular events? How do thyroid function abnormalities affect cardiac structure and function, and can these changes improve after thyroid function returns to normal? Researchers will compare participants with normal thyroid function, subclinical thyroid dysfunction, and overt thyroid dysfunction to evaluate differences in cardiovascular outcomes.The study includes retrospective and prospective cohorts. Researchers will collect thyroid function tests, clinical records, electrocardiograms, echocardiographic findings, treatment information, and long-term cardiovascular outcomes. Participants in the prospective cohort will undergo follow-up, with biological samples collected for exploratory analyses when appropriate and with informed consent. No experimental treatments will be assigned.

Studieoversigt

Detaljeret beskrivelse

The Thy-CVD Cohort is a nationwide, multicenter, observational study combining retrospective and prospective cohorts to investigate the associations of thyroid function abnormalities and dynamic thyroid hormone exposure with cardiac remodeling and long-term cardiovascular outcomes.The study will enroll adults aged 18 years or older with available thyroid function testing. Participants will be classified into five groups according to thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4) levels: euthyroidism, subclinical hyperthyroidism, overt hyperthyroidism, subclinical hypothyroidism, and overt hypothyroidism.The retrospective cohort will include patients evaluated between January 2018 and August 2026. The prospective cohort will enroll participants beginning in September 2026, with standardized longitudinal follow-up planned through 2036.Repeated thyroid function measurements will be used to evaluate the severity, duration, variability, and cumulative burden of thyroid hormone abnormalities, as well as the time required to achieve and maintain normal thyroid function.The primary outcome is the first occurrence of a composite major adverse cardiovascular event, including cardiovascular death, hospitalization for heart failure, myocardial infarction, ischemic or hemorrhagic stroke, and serious arrhythmias requiring clinical intervention.Secondary outcomes include individual cardiovascular events, all-cause mortality, and changes in cardiac structure and function assessed by serial echocardiography. The study will also investigate cardiac reverse remodeling and residual cardiovascular risk after normalization of thyroid function.Exploratory analyses will evaluate associations between thyroid treatment strategies, thyroid function control, and cardiovascular outcomes. Biological samples and clinically obtained residual cardiovascular tissues may be analyzed in selected participants to investigate potential molecular mechanisms.This is an observational study. All clinical treatments and examinations will be determined by treating physicians according to routine clinical practice, without investigator-assigned interventions.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

10000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Shaanxi
      • Xi'an, Shaanxi, Kina, 710061
        • First Affiliated Hospital of Xi'an Jiantong University
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Guoliang Li
        • Ledende efterforsker:
          • Yang Yan

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Adults aged 18 years or older who undergo thyroid function testing at the First Affiliated Hospital of Xi'an Jiaotong University and participating medical centers across China. The study population includes individuals with normal thyroid function, subclinical hyperthyroidism, overt hyperthyroidism, subclinical hypothyroidism, and overt hypothyroidism. The retrospective cohort includes eligible patients identified from existing medical records between January 2018 and August 2026. The prospective cohort consecutively enrolls eligible participants beginning in September 2026 for longitudinal follow-up. Thyroid function status, cardiovascular risk factors, treatment information, cardiac imaging findings, and clinical outcomes will be collected. Biological sample availability is not required for enrollment.

Beskrivelse

Inclusion Criteria:

  1. Adults aged 18 years or older.
  2. At least one thyroid function assessment, including thyroid-stimulating hormone (TSH) and free triiodothyronine (FT3) and/or free thyroxine (FT4).
  3. Available and traceable clinical information, including demographic characteristics, medical history, laboratory findings, imaging results, or follow-up records.
  4. Thyroid functional status can be determined from available thyroid function measurements and corresponding laboratory reference ranges.
  5. For the prospective cohort, participants must provide informed consent for study participation and be willing to undergo longitudinal follow-up.

Exclusion Criteria:

  1. Thyroid functional status cannot be reliably determined from available clinical and laboratory data.
  2. Key clinical information is substantially incomplete or unreliable, preventing adequate assessment of the primary outcome.
  3. No reliable information is available to ascertain cardiovascular outcomes or vital status after baseline.
  4. Duplicate enrollment; only the first eligible record will be retained.
  5. Other circumstances that, in the investigator's judgment, make the individual unsuitable for study participation or long-term follow-up.

Biospecimen availability is not required for enrollment. Participants without available biological samples remain eligible if they meet the other inclusion and exclusion criteria.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: OTHER

Kohorter og interventioner

Gruppe / kohorte
Retrospective Cohort

Adults aged 18 years or older who underwent thyroid function testing at participating centers between January 2018 and August 2026 will be retrospectively identified through existing electronic health records. Clinical data, including thyroid function measurements (TSH, FT3, and FT4), thyroid disease diagnoses, treatment history, cardiovascular risk factors, electrocardiographic and echocardiographic findings, and clinical outcomes, will be collected from existing medical records and follow-up databases. Participants will be classified according to baseline thyroid function status and longitudinal thyroid hormone exposure patterns, where repeated measurements are available. No additional clinical interventions will be performed.

Prospective Cohort

Adults aged 18 years or older undergoing thyroid function testing at participating centers will be prospectively enrolled beginning in September 2026 and followed longitudinally. Baseline and follow-up data will include thyroid function measurements (TSH, FT3, and FT4), thyroid disease characteristics, treatment information, cardiovascular risk factors, electrocardiographic and echocardiographic findings, and clinical outcomes. Repeated thyroid function assessments will be used to characterize longitudinal hormone exposure patterns and their associations with cardiac remodeling and cardiovascular events. Biological samples may be collected with informed consent for exploratory analyses. Clinical management will follow routine medical practice without investigator-assigned interventions.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to First Major Adverse Cardiovascular Event (MACE)
Tidsramme: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Time from baseline to the first occurrence of major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, hospitalization for heart failure, myocardial infarction, ischemic or hemorrhagic stroke, or serious arrhythmia requiring clinical intervention, including new-onset atrial fibrillation and sustained ventricular arrhythmias. The outcome will be measured as time to the first qualifying event in days. Events will be identified through medical records, hospitalizations, clinical follow-up, and available death records. Only the first qualifying event per participant will be counted.

Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
New-Onset Atrial Fibrillation
Tidsramme: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Number of participants without documented atrial fibrillation at baseline who develop newly diagnosed atrial fibrillation during follow-up. Atrial fibrillation will be identified by 12-lead electrocardiography, ambulatory electrocardiographic monitoring, or documented clinical diagnoses in medical records. The outcome will be reported as the number of participants with newly diagnosed atrial fibrillation.

Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.
Heart Failure Events
Tidsramme: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Number of participants experiencing clinically documented heart failure events during follow-up. Heart failure will be identified through physician-documented diagnoses, hospitalization records, and available clinical assessments. The outcome will be reported as the number of participants with documented heart failure events.

Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.
Coronary Artery Disease Events
Tidsramme: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Number of participants experiencing clinically documented coronary artery disease events during follow-up. Events will be identified from medical records, clinical diagnoses, coronary angiography, and available coronary imaging reports. The outcome will be reported as the number of participants with documented coronary artery disease events.

Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Guoliang Li, First Affiliated Hospital Xi'an Jiaotong University
  • Ledende efterforsker: Yang Yan, First Affiliated Hospital Xi'an Jiaotong University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

11. november 2026

Primær færdiggørelse (Anslået)

1. august 2046

Studieafslutning (Anslået)

1. august 2046

Datoer for studieregistrering

Først indsendt

8. november 2026

Først indsendt, der opfyldte QC-kriterier

13. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner